CD34 and Schnyder corneal dystrophy: By contrast and though limited to transition edits, which are unable to revert the SCD mutation itself, base editing in CD34+ cells was recently employed by two landmark studies with potentially great significance for the future of SCD therapy and for the clinical translation of the therapy of hemoglobinopathies in general.